Every summer, biopharma commercial teams pause for mid-year business reviews. Most of that time goes to performance: what the numbers say, where the gaps are, what the second half requires. Far less goes to the question underneath the numbers: what has changed in the accounts themselves?
Accounts evolve continuously. Ownership changes hands. A health system adopts a new protocol. A stakeholder who carried little influence in January now shapes the decision. None of this reflects on the quality of the original plan. It reflects the market we sell into, where the customer is an organization, and organizations keep moving.
The teams that navigate this well are not the ones that predicted every shift. They are the ones with a discipline for taking stock. In our work with commercial teams, 4 questions come up again and again at this point in the year. Here is how we think about each.
How do I know when an account plan needs to be refined?
Not every change warrants a response. The discipline has two parts: identifying what has shifted, then judging whether the magnitude justifies refining the engagement plan.
A useful assessment runs across four dimensions:
- Marketplace. What has changed in the local healthcare economy: consolidation, service line investments, CMS penalties, and quality measures the account is now managing against?
- Competitors. Who has gained ground in the account, and through which relationships or contracts?
- Ownership. Has the account itself changed hands, joined a system, or reorganized how decisions flow?
- Stakeholders. Who has entered, who has left, and whose influence has grown or faded since the plan was written?
Then the judgment: is this a footnote or a plot change? A new quality initiative may simply sharpen an existing message. A change in ownership often reshapes the entire engagement approach. The critical skill is distinguishing between the two, and most teams have never been asked to practice it.
What account changes should biopharma teams monitor between planning cycles?
The most consequential shifts are usually the quiet ones: a committee restructured, a decision moved from the practice to the system, or a medical director’s expanded role. They rarely announce themselves the way a formulary change does, and they rarely appear in a dashboard.
That is why taking stock works best as a team conversation, not an individual exercise. Reps, account managers, field medical, and access colleagues each see a different face of the account. Put those perspectives in one room and a clearer picture emerges. Leave them separate and the picture remains incomplete.
August is a natural point to take stock of changes in the account, and ensure insights are reflected in second half execution as well as assumptions for 2027 planning.
How do I build continuous account planning discipline into my commercial team?
Three best practices to consider:
- Leverage existing business review processes. Incorporate ecosystem/account changes to existing business reviews and one-on-ones rather than creating a new meeting. The four dimensions become a standing agenda item.
- Make leaders the askers. When managers routinely ask “what has shifted, and does it matter?” in coaching conversations, teams start monitoring consistently.
- Close the loop visibly. When a team surfaces a shift and the account plan actually changes, share it. Nothing builds the habit faster than evidence that the observations lead to insights, which inform key actions.
Teams that build proficiency in identifying account changes and making adjustments appropriately are more likely to drive more relevant customer engagement…Then, there is the question which teams ask once they have decided to act.
Who provides account planning training for biopharma commercial teams?
Several firms do, so the better question is what to look for.
- A planning approach tied to your customer model. Content built for a retail-heavy market will not serve a team calling on IDNs, organized providers, and payer-influenced accounts.
- Refinement built in, not just the annual event. Planning that only happens in January produces plans that drift. Strong programs teach teams to assess what has shifted and judge when refinement is warranted.
- Coaching for leaders, not just tools for the field. Plans improve when managers know how to pressure-test them.
- Biopharma depth. Planning mechanics are teachable anywhere. Judgment about marketplace, stakeholders, and access dynamics requires a partner who works in this industry every day.
Building that discipline is core to WLH’s Commercial Excellence practice. If you see room for growth in your team’s account planning and execution approach, we would welcome a conversation.
